Stay updated on Helix BioPharma Press Releases

Sign up to get notified when there's something new on the Helix BioPharma Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Helix BioPharma Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Helix BioPharma Corp. has added several new presentations and abstracts from 2017 to 2023, while notable deletions include the appointment of a new CFO and multiple asset purchase agreements related to their immune-oncology portfolio.
    Difference
    100%
    Check dated 2024-12-28T21:20:14.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Helix BioPharma Corp. has appointed James B. Murphy as Chief Financial Officer and amended acquisition agreements to finalize share consideration ahead of potential financing.
    Difference
    93%
    Check dated 2024-12-14T11:54:08.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has entered into an asset purchase agreement to acquire an oral chemotherapy compound, marking a significant development in its portfolio, while previous announcements regarding share consolidation and executive resignations have been removed.
    Difference
    23%
    Check dated 2024-12-07T09:39:47.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor, expanding its immune-oncology portfolio, while the announcement regarding the grant of stock options has been removed.
    Difference
    24%
    Check dated 2024-11-30T00:16:59.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has announced the issuance of a new U.S. patent for its immuno-oncology therapies, while several sections of their website, including stock price news and corporate governance, have been removed.
    Difference
    75%
    Check dated 2024-11-22T16:28:21.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has entered a non-binding letter of intent to acquire Laevoroc Group’s oncology assets and announced the resignation of its CFO, while also attending the World ADC San Diego event.
    Difference
    100%
    Check dated 2024-11-15T13:08:26.000Z thumbnail image

Stay in the know with updates to Helix BioPharma Press Releases

Enter your email address, and we'll notify you when there's something new on the Helix BioPharma Press Releases page.